

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE **FAX RECEIVED**

In re the application of:

Dunkley et al.

Application No.: 10/822,850

Filed: 04/09/2004

For: AEROSOLIZATION APPARATUS WITH  
AIR INLET SHIELD

JAN 23 2009

Group Art Unit: 3771

OFFICE OF PETITIONS

Examiner: Douglas, Steven O.

Atty. Docket No.: 0198.00

Date: January 23, 2009

CERTIFICATE OF FACSIMILE

I hereby certify that this correspondence is being facsimile transmitted to the Commissioner of Patents at facsimile number: (571)272-3282 on January 23, 2009

Signed: April Skovmand

April Skovmand

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.56 AND 1.97(b)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:


The reference(s) listed in the attached PTO Form 1449, cop(ies) of which is attached (when necessary), may be material to examination of the above-identified patent application. Applicants submit the reference(s) in compliance with their duty of disclosure pursuant to 37 CFR §§ 1.56 and 1.97. The Examiner is requested to make the reference(s) of official record in this application.

Applicant specifically notes that References "S" and "T" are co-pending with the present case, as well as co-owned by Novartis.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that the reference(s) indeed constitutes prior art.

This Information Disclosure Statement is believed to be filed within three months of the filing date of a national application other than a continued prosecution application, within three months of the date of entry of the national stage in an international application, before the mailing of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination. Accordingly, it is believed that no fees are due in connection with the filing of this Information Disclosure Statement. However, if it is determined that any fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 190134. (Order No. 0198.00).

Respectfully submitted,  
Novartis Pharmaceuticals Corporation,

/Michael J. Mazza/  
  
Michael J. Mazza  
Reg. No. 30,775

150 Industrial Road  
San Carlos, CA 94070  
Telephone: (650) 283-6790

\*\*\*\*\*  
\*\*\* RX REPORT \*\*\*  
\*\*\*\*\*

RECEPTION OK

TX/RX NO	5416
RECIPIENT ADDRESS	4089714660
DESTINATION ID	
ST. TIME	01/23 18:22
TIME USE	01'13
PGS.	11
RESULT	OK

FAX RECEIVED

JAN 23 2009

OFFICE OF PETITIONS